Last week, J&J JNJ announced plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the United States as the Trump administration considers imposing tariffs...
J&J JNJ stock has risen more than 6% in the past month. The reason behind the increase was a strong-than-expected fourth-quarter earnings report and an optimistic outlook for the Innovative Medicine segment...
Key TakeawaysJNJ beat Q4 earnings and sales estimates, with its Innovative Medicines Unit outperforming expectations.Sales in the unit rose 4.4% YOY to $14.33 billion, led by key drugs such as Darzalex,...
Johnson & Johnson’s JNJ fourth-quarter 2024 earnings came in at $2.04 per share, which beat the Zacks Consensus Estimate of $2.00. Earnings declined 10.9% from the year-ago period. Adjusted earnings...
Key TakeawaysThe Zacks Consensus Estimate for JNJ Q4 sales and earnings is $22.5 billion and $2.01 per share, respectively.JNJ's performance has impressed, as the company exceeded earnings expectations...
The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally
JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive
For Immediate ReleaseChicago, IL – January 15, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...